Contribution of neuroinflammation in burning mouth syndrome: indications from benzodiazepine use.
Characterized by burning and painful oral sensations in absence of clinically significant mucosal abnormalities, the burning mouth syndrome is, despite numerous researches made, basically idiopathic and, consequently, difficult to treat effectively. Therapy with tricyclic antidepressants and benzodiazepines has been proposed, although the exact pathomechanism is not clear. The objective of this study is to define the possible reasons for the efficacy of benzodiazepines in the treatment of the burning mouth syndrome. Starting from the report of eight cases successfully treated with prazepam, the present authors examined the clinical features and the evidence from literature that support the possibility of a role of neuroinflammation in the pathogenesis of the burning mouth syndrome. Available data suggest that the nervous system could be crucial in the pathogenesis of the syndrome (altered perception of pain, disturbance of neural transmission, increased excitability, negative involvement of trigeminal-vascular system), and the present authors' experience lets them suppose a role for neuroinflammation. This hypothesis could also explain the positive response to benzodiazepines in some patients. The important role of neuroinflammation in dermatologic and oral diseases has been only recently investigated and acknowledged. Further studies on the connection between neuroinflammation and burning mouth syndrome could open interesting perspectives in the understanding and management of this difficult clinical condition.
Department of Social and Territorial Medicine, Section of Dermatology, University of Messina, Messina, Italy. f.guarneri@tiscali.it
Fabrizio
F
Guarneri
Claudio
C
Guarneri
Herbert
H
Marini
D000328:Adult; D002054:Burning Mouth Syndrome / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D018757:GABA Modulators / Q000008:administration & dosage*; D006801:Humans; D009443:Neuritis / Q000150:complications / Q000188:drug therapy*; D010865:Pilot Projects; D011222:Prazepam / Q000008:administration & dosage*; D016896:Treatment Outcome
D018757:GABA Modulators; D011222:Prazepam